Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Journal of Acquired Immune Deficiency Syndromes (1999)|January 23, 2013
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 resultsJürgen K Rockstroh, Edwin DeJesus, Keith Henry, et al.Lancet (London, England)|July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialEdwin DeJesus, Jürgen K Rockstroh, Keith Henry, et al.JAMA|July 14, 2004
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trialJoel E Gallant, Schlomo Staszewski, Anton L Pozniak, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2006
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysisAnton L Pozniak, Joel E Gallant, Edwin DeJesus, et al.The New England Journal of Medicine|January 20, 2006
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIVJoel E Gallant, Edwin DeJesus, José R Arribas, et al.The Pediatric Infectious Disease Journal|March 12, 2015
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppressionXavier Saez-Llorens, Elizabeth Castaño, Mobeen Rathore, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsAndrew Zolopa, Paul E Sax, Edwin DeJesus, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysisJose R Arribas, Anton L Pozniak, Joel E Gallant, et al.Lancet (London, England)|July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksPaul E Sax, Edwin DeJesus, Anthony Mills, et al.The Journal of Infectious Diseases|March 28, 2013
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 resultsJoel E Gallant, Ellen Koenig, Jaime Andrade-Villanueva, et al.Pageof 4